The Kyowa Kirin Sponsored Hypophosphatemia Program

Sponsored, no-charge genetic testing
US and Canada

KKHP Invitae logo

What is the Kyowa Kirin Sponsored Hypophosphatemia Program?

  • A no-charge genetic testing and counseling program for patients being evaluated for a diagnosis of X-linked hypophosphatemia (XLH) or tumor induced osteomalacia (TIO,) who meet certain age requirements and other eligbility criteria
  • A program intended to improve patient safety and quality of care by shortening the time to an accurate diagnosis, facilitating prompt confirmatory testing, and helping patients with XLH or TIO meet payor coverage requirements
  • Healthcare professionals or patients using this program are not obligated to recommend, purchase, order, prescribe, promote, administer, use, or support any Kyowa Kirin product
  • No patients, healthcare professionals, or payers, including government payers, are billed for this program

Genetic Testing Panel and Counseling

Certain hypophosphatemic disorders have an underlying genetic cause. It is equally important to exclude genetic causes of hypophosphatemia when evaluating for a possible diagnosis of TIO. An accurate diagnosis may impact the clinical management of the condition, including customizing care to a patient's specific needs.

  • About XLH

    • XLH, the most common form of genetic hypophosphatemia, is caused by pathogenic variants in the PHEX gene.1 XLH is an X-linked condition, meaning that the genetic variant (located on the X chromosome) only needs to exist in one copy of a patient’s genes to cause the condition.
    • Women with XLH have a 50% chance of passing the condition to their children, regardless of gender, while men with XLH will pass it on to all their daughters and none of their sons.2

  • About TIO

    • TIO is a paraneoplastic condition of abnormal phosphorus and vitamin D metabolism caused by small, benign endocrine tumors that secrete the phosphaturic hormone, fibroblast growth factor 23 (FGF23), leading to impaired bone metabolism.3

Testing options

This program offers testing with the Kyowa Kirin Sponsored Hypophosphatemia Panel
Note: Re-requisitions are not available through this sponsored testing program
The panel tests for 13 genes

  • KKHP - Test Panel

    Kyowa Kirin Sponsored Hypophosphatemia 13 Gene Panel

    CLCN5, CTNS, CYP2R1, CYP27B1, DMP1, ENPP1, FGF23, OCRL, PHEX, SLC34A1, SLC34A3, SLC9A3R1, VDR

Woman smiling while providing genetic expert support

Genetic counseling services

Individuals in the US and Canada tested through this program are eligible for post-test genetic counseling to help them understand their test results. This service is made available by Invitae at no charge as part of the program. Patients can access genetic counseling by scheduling a session through their patient portal or by contacting Invitae Client Services at 1-800-436-3037 and asking to schedule a genetic counseling appointment.

    • If you are using an outside lab to collect the sample, it is recommended that you fax the TRF to Invitae at 415-276-4164
    • Kyowa Kirin DOES NOT compensate HCPs or labs for specimen collection or handling
    • Kyowa Kirin will not receive any individual test result data, personally identifiable information, or physician ordering information. Any data that may be transmitted will be de-identified and aggregated

      Questions? Contact Invitae
    Contact us

About Kyowa Kirin
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based global specialty pharmaceutical company with a more than 70-year heritage, the company applies cutting-edge science, including expertise in antibody research and engineering, to address the needs of patients across multiple therapeutic areas. Across its four regions—Japan, Asia Pacific, North America and EMEA/International—Kyowa Kirin focuses on its purpose, which is to make people smile, and is united by its shared values of commitment to life, teamwork, innovation and integrity. Learn more about the company at www.kyowakirin.com.

References

1. X-linked hypophosphatemia. Genetic and Rare Diseases Information Center (GARD) website. Updated 2018. Accessed January 3, 2019. https://rarediseases.info.nih.gov/diseases/12943/x-linked-hypophosphatemia.
2. Ruppe MD. X-linked hypophosphatemia. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews. (Internet). Seattle (WA): University of Washington, Seattle; 1993-2019.
3. Dahir K, et al. Diagnosis and management of tumor-induced osteomalacia: perspectives from clinical experience. J Endocr Soc. 2021;5(9):bvab099.

Disclaimer: While Kyowa Kirin provides financial support for the Program, tests and services are performed by Invitae. Healthcare professionals must confirm that patients meet program eligibility criteria to use the program. Kyowa Kirin may receive deidentified patient data from this program, but at no time will Kyowa Kirin receive patient identifiable information. Genetic testing and counseling is available in the US and Canada. Healthcare professionals and patients who participate in this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any other products or services from Invitae, Kyowa Kirin, or any other third party.